ReviewFrontiers in oncology2021
Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Efficacy and Safety of Fusion Imaging in Radiofrequency Ablation of Hepatocellular Carcinoma Compared to Ultrasound: A Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Perfusion Patterns of Pleura-Based Pulmonary Sarcoma Metastases on Contrast-Enhanced Ultrasound (CEUS): A Single-Center Retrospective Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Technical and clinical outcomes of microwave ablation for HCC: a single-center retrospective analysis of percutaneous ultrasound-guided, intraoperative ultrasound-guided and CT hepatic arteriography-guided approaches.La Radiologia medica · 2026Article
- Low-mechanical-index B-mode phase-inversion harmonic imaging significantly improves hepatic lesion conspicuity during Sonazoid Kupffer phase: a prospective comparative study.Ultrasonography (Seoul, Korea) · 2026Article
- The value of contrast-enhanced ultrasound fusion imaging in percutaneous liver biopsy for liver lesions invisible on conventional B-mode ultrasound.Quantitative imaging in medicine and surgery · 2025Article
- Targeting the invisible: precision fiducial marker placement in poorly visible liver tumors prior to percutaneous ablation using real-time image fusion guidance.Frontiers in radiology · 2025Article
- Clinical study on ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma.American journal of translational research · 2025Article
- Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study.Journal of liver cancer · 2024Article
- No-Touch Radiofrequency Ablation for Early Hepatocellular Carcinoma: 2023 Korean Society of Image-Guided Tumor Ablation Guidelines.Korean journal of radiology · 2023Review
- Article
- Loco-regional treatment of hepatocellular carcinoma: Role of contrast-enhanced ultrasonography.World journal of hepatology · 2022Review
- Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect?Ultrasonography (Seoul, Korea) · 2022Article
- Multiple Light-Activated Photodynamic Therapy of Tetraphenylethylene Derivative with AIE Characteristics for Hepatocellular Carcinoma via Dual-Organelles Targeting.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ultrasound (US) imaging technology, including contrast-enhanced US (CEUS) and fusion imaging, has experienced radical improvement, and advancement in technology thus overcoming the problem of poor conspicuous hepatocellular carcinoma (HCC). On CEUS, the presence or absence of enhancement distinguishes the viable portion from the ablative necrotic portion. Using volume data of computed tomography (CT) or magnetic resonance imaging (MRI), fusion imaging enhances the three-dimensional relationship between the liver vasculature and HCC. Therefore, CT/MR-US fusion imaging provides synchronous images of CT/MRI with real-time US, and US-US fusion imaging provides synchronous US images before and after ablation. Moreover, US-US overlay fusion can visualize the ablative margin because it focuses the tumor image onto the ablation zone. Consequently, CEUS and fusion imaging are helpful to identify HCC with little conspicuity, and with more confidence, we can perform ablation therapy. CEUS/fusion imaging guidance has improved the clinical effectiveness of ablation therapy in patients with poor conspicuous HCCs. Therefore; this manuscript reviews the status of CEUS/fusion imaging guidance in ablation therapy of poor conspicuous HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.